Literature DB >> 15002733

Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.

Dhanasekaran Muralikrishnan1, Manuchair Ebadi, Holly M Brown-Borg.   

Abstract

We investigated the neuroprotective effect of the dopamine agonist, 3-PPP [3-(3-hydroxyphenyl)-N-propylpiperidine] against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. MPTP (30 mg/kg, i.p., twice, 16 h apart) causes significant dopamine depletion in nucleus caudatus putamen (NCP) by 1 week. 3-PPP had no effect on the monoamine oxidase-B activity (MAO-B) activity in NCP. 3-PPP did not affect dopamine uptake, whereas mazindol significantly blocked the uptake of dopamine dose dependently. MPTP-induced behavioral changes in mice were not reduced by pretreatment with 3-PPP. This dopamine agonist did not prevent dopamine depletion caused by MPTP. MPP+ (20 microM) significantly inhibited the cell proliferation of SH-SY5Y dopaminergic neuronal cells. 3-PPP had no effect on the SH-SY5Y neuronal cell growth in culture and did not block the MPP(+)-induced cytotoxicity. This study shows that the dopamine agonist 3-PPP failed to protect against MPTP-induced dopaminergic neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15002733     DOI: 10.1023/b:nere.0000013740.53483.39

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  45 in total

1.  A multicenter trial of ropinirole as adjunct treatment for PD.

Authors:  J S Jeret
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

2.  Behavioural and chemical changes in mice during morphine dependence development, withdrawal and naloxone administration.

Authors:  K P Mohanakumar; P P Sood
Journal:  Cell Mol Biol       Date:  1985       Impact factor: 1.770

3.  Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.

Authors:  Y Kitamura; T Kosaka; J I Kakimura; Y Matsuoka; Y Kohno; Y Nomura; T Taniguchi
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

4.  Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.

Authors:  K P Mohanakumar; D Muralikrishnan; B Thomas
Journal:  Brain Res       Date:  2000-05-12       Impact factor: 3.252

5.  Bromocriptine in Parkinsonism.

Authors:  D B Calne; P F Teychenne; L E Claveria; R Eastman; J K Greenacre; A Petrie
Journal:  Br Med J       Date:  1974-11-23

6.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

Authors:  K Chiba; A Trevor; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

7.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

Review 8.  Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.

Authors:  M F Piercey
Journal:  Clin Neuropharmacol       Date:  1998 May-Jun       Impact factor: 1.592

9.  The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.

Authors:  W Schultz; E Scarnati; E Sundström; T Tsutsumi; G Jonsson
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

10.  Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.

Authors:  N Arai; M Isaji; H Miyata; J Fukuyama; E Mizuta; S Kuno
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.